Nilotinib and dasatinib each appear to be safe and more effective than the BCR-ABL tyrosine kinase inhibitor imatinib for inducing complete cytogenetic response and major molecular response in patients with newly diagnosed chronic myeloid leukemia, according to the findings of two randomized phase III studies involving a total of 1,365 CML patients.The studies comparing the second-generation BCR-ABL kinase inhibitors with imatinib were published online in the June 5 issue of the New England Journal...